From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
MedlinePlus a682088
555-57-7 YesY
C02KC01 C02LL01
PubChem CID 4688
DrugBank DB01626 N
ChemSpider 4526 YesY
Chemical data
Formula C11H13N
159.23 g/mol
 N (what is this?)  (verify)

Pargyline (Eutonyl) is an irreversible non-selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 0.01152micromol/L and for MAO-B is 0.00820micromol/L.) [1] [2] It was brought to market in the US and the UK by Abbott in 1963 as "Eutonyl" as an antihypertensive drug, and was one of several other MAO inhibitors brought to market in the 1960s, along with nialamide, isocarboxazid, phenelzine, and tranylcypromine.[3]:146[4]:60[5]

As of 2007 the drug was discontinued[6] and as of 2014 there were no generic versions in the US.[7]

See also[edit]


  1. ^ Fisar Z, Hroudová J, Raboch J. (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.". Neuro Endocrinol Lett. 31 (5): 645–56. PMID 21200377. 
  2. ^ Murphy DL, Karoum F, Pickar D et al. (1998). "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)". J. Neural Transm. Suppl. 52: 39–48. doi:10.1007/978-3-7091-6499-0_5. PMID 9564606. 
  3. ^ Edward Shorter, A historical dictionary of psychiatry. Oxford University Press, Inc 2005. ISBN 0195176685
  4. ^ William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975) ISBN 0844731676
  5. ^ Council on Drugs New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl) JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.
  6. ^ W. Steven Pray Interactions Between Nonprescription Products and Psychotropic Medications US Pharmacist. 2007;32(11):12-15.
  7. ^ FDA Eutonyl in the Drugs@FDA Database Accessed July 19, 2014